top of page
Grandparents Running Along Beach With Grandchildren On Summer Vacation.jpg

Phap Medical

Disruptive Blood Pump Technology

Gentle Pulsatile Flow

"Revolutionizing Cardiac Care To Save More Lives"

MOTIVATION 01

MOTIVATION

HEART DISEASE

REMAINS THE LEADING CAUSE OF DEATH IN AMERICA TODAY

OVER 127 MILLION

PEOPLE DEVELOP HEART DISEASE EACH YEAR IN THE U.S. ALONE

EVERY 33 SECONDS

ONE OF US WILL SUCCUMB TO A CARDIOVASCULAR EVENT

OVER 694 THOUSAND

AMERICANS WERE CLAIMED BY HEART DISEASE IN 2021 ALONE

IMAGINE THE ENTIRE POPULATION OF A CITY

TAKEN FROM US EACH YEAR​

WASHINGTON, LAS VEGAS, PORTLAND OR BOSTON

 â€‹THESE ARE NOT JUST NUMBERS

THEY ARE LOVED ONES, OUR FAMILY AND FRIENDS

PHAP MEDICAL'S TEAM IS HIGHLY MOTIVATED TO SIGNIFICANTLY REDUCE THESE HORRENDOUS STATISTICS

OUR NOVEL TECHNOLOGY COULD ONE DAY BE RESPONSIBLE FOR SAVING COUNTLESS LIVES

MISSION

MISSION

WE ARE DEVELOPING A SUITE OF NEXT GENERATION PRODUCTS

ADDRESSING THE URGENT AND UNMET NEEDS OF PATIENTS IN ACUTE CARDIAC CRISES

THESE DESIGNS ARE CATHETER-DEPLOYED HEART ASSIST PUMPS

( Percutaneous Heart Assist Pumps )

( P.H.A.P. DEVICES )

OUR TEAM'S MISSION IS TO INTRODUCE ADVANCED FUNCTIONALITY INTO THIS GROWING MARKET

WE CONTINUOUSLY COLLABORATE WITH LEADING MEDICAL PROFESSIONALS SKILLED IN CARDIAC CARE

ENABLING US TO IDENTIFY ESSENTIAL AREAS OF NEEDED IMPROVEMENT IN THIS SECTOR

OUR DESIGNS ADDRESS ALL AREAS OF OPPORTUNITIES REALIZED THROUGH THESE CONVERSATIONS

EVIDENT BY THE UNIQUE COMBINATION OF CAPABILITIES FOUND THROUGHOUT OUR FAMILY OF PRODUCTS

SMARTLY POSITIONING US TO OVERCOME THE CHALLENGES FOUND IN THE CURRENT GLOBAL MARKET

WE FIND PRIDE IN ADDRESSING THESE CHALLENGES AS WE ADVANCE OUR NOVEL SOLUTIONS

CREATED TO HELP MEDICAL TEAMS DELIVER SAFER, MORE EFFECTIVE CARE FOR PATIENTS IN CRITICAL NEED

PRIORITIES

PRIORITIES

( LOW CYCLE RATE - HIGH OUTPUT )

PERISTALSIS HEART ASSIST PUMPS ARE REVOLUTIONARY IN THE FIELD OF MECHANICAL CIRCULATORY SUPPORT

OUR (PATENT PENDING) TECHNOLOGIES PRODUCE HIGH FLOW AT LOW CYCLE RATES USING OUR GENTLE PERISTALSIS DESIGN

( PULSATILE FLOW )

YOUR NATURAL HEARTBEAT CREATES STRONG STEADY PULSATILE BLOOD FLOW THROUGHOUT YOUR BODY'S CIRCULATORY SYSTEM

SIMILARLY, OUR DESIGN'S PULSATILE RHYTHM PRODUCES A GENTLE , PHYSIOLOGIC BLOOD FLOW OF LIFE-SUSTAINING BENEFITS

( ENHANCED DIRECTIONAL CONTROL )

PHAP MEDICAL IS BRINGING NOVEL CAPABILITIES TO THE MARKET WITH OUR DIRECTIONAL CONTROL TECHNOLOGY

OUR INNOVATION PROVIDES STANDARD, REVERSE AND BI-DIRECTIONAL FLOW ENHANCING OPTIONS IN COMPLEX CONDITIONS

( REDUCED DESTRUCTION OF RED BLOOD CELLS )

THE DESTRUCTION OF RED BLOOD CELLS IS CALLED (HEMOLYSIS) AND THIS MAY OCCUR WHEN USING A HEART ASSIST DEVICE

OUR PERISTALSIS TECHNOLOGY MIMICS NATURES METHOD OF GENTLY MOVING FLUIDS THROUGHOUT THE BODY

LIKE THE PULSE OF YOUR HEART WE UTILIZE FLUID DISPLACEMENT, NOT SPINNING IMPELLERS OR MOTORS

( EXTENDED DURATION )

PROVIDING SEVERAL WEEKS OF CRITICAL CARE TO PATIENTS IN NEED REQUIRES GENTLE BLOOD HANDLING TECHNOLOGY

BY REDUCING THE RISKS OF BLOOD DAMAGE AND NEED FOR TRANSFUSIONS WE CAN EXTEND OUR OPERATIONAL WINDOW

( REDUCED CATHETER DIAMETER )

WITH NO MOTORS OR SPINNING IMPELLERS IN OUR CATHETER DESIGN WE CAN MAINTAIN A SMALL INSERTION DIAMETER

RESULTING IN VERY MANEUVERABLE CATHETER THAT ELIMINATES THE NEED OF A SURGICAL CUT-DOWN AND REDUCES RISKS

( EXPANDED PATIENT ELIGIBILITY )

BY PRIORITIZING ALL OF THE ABOVE ABILITIES WE BROADEN THE ACCEPTABLE PATIENT PROFILE OF USE FOR OUR PRODUCTS

CREATING THE LIKELIHOOD THAT OUR DEVICES WILL DOMINATE A LARGER SHARE OF THE MARKET THAN OTHER PRODUCTS

OVERVIEW

OVERVIEW

GLOBAL HEART ASSIST PUMPS

DEMAND FOR ADVANCED HEART CARE SOLUTIONS

THE GLOBAL MARKET FOR VENTRICULAR ASSIST DEVICES (VADs) WAS VALUED AT $1.8 BILLION IN 2020

THIS MARKET IS EXPECTED TO GROW RAPIDLY AT UP TO 8% ANNUAL RATE THROUGH 2028

WORLD WIDE COST OF CARE

AGING POPULATIONS DRIVE INCREASES IN RATES OF HEART DISEASE, DIABETES, AND HYPERTENSION

GROWTH OF GLOBAL HEART FAILURE CARE COST HAVE BEEN PROJECTED AS HIGH AS

( $30.7 BILLION IN 2012 TO $1.1 TRILLION BY 2035 )

FUTURE OF HEART ASSIST TECHNOLOGIES

HEART FAILURE REMAINS A LEADING CAUSE OF DEATH AROUND THE GLOBE AS IT CONTINUES ITS ANNUAL GROWTH

THE NEED FOR HEART ASSIST TECHNOLOGIES PROVIDING CARDIAC SUPPORT WILL ALSO CONTINUE TO GROW

CURRENT ASSIST TECHNOLOGIES, SUCH AS IMPELLER PUMPS AND INTRA-AORTIC BALLOON PUMPS

ARE PLAYING A CRITICAL ROLE IN TREATING TODAY'S ACUTE CONDITIONS

HOWEVER PERFORMANCE LIMITATIONS LEAVE SIGNIFICANT OPPORTUNITY FOR NEXT GENERATION PRODUCTS

APPLICATION

APPLICATION

CARDIOGENIC SHOCK  -  MYOCARDIAL INFARCTION  -  ACUTE DECOMPENSATED HEART FAILURE

POST-CARDIOTOMY SHOCK  -  CARDIOMYOPATHIES  -  HIGH-RISK (PCI) PROCEDURES

ARE EXTREMELY SERIOUS EVENTS THAT CAN LEAVE A PATIENT'S HEART IN A SEVERELY WEAKENED CONDITION

CREATING CRITICAL MOMENTS WHEN THE PATIENT'S BLOOD FLOW CAN DROP TO LIFE-THREATENING LEVELS

RAPID DEPLOYMENT OF A HEART ASSIST DEVICE IS USED TO STABILIZE PATIENTS ENDURING SUCH CONDITIONS

​PROVIDING MECHANICAL SUPPORT TO ASSURE THAT THE PATIENT MAINTAINS PROPER BLOOD FLOW LEVELS​ WHILE

​SUPPORTING CRITICAL ORGANS IN BODY'S CIRCULATORY SYSTEM SUCH AS THE HEART, KIDNEYS AND BRAIN

THESE DEVICES DURING AN ER CRISES GIVE MEDICAL TEAMS PRECIOUS TIME TO EVALUATE TREATMENTS OPTIONS

​EVEN AFTER THE INITIAL CRISES IS OVER AND THE PATIENT IS STABLE THE WEAKENED HEART MAY REQUIRE

AN EXTENDED USE DEVICE CAPABLE OF SUPPORTING WEEKS OF CRITICAL CARE IN LONGER RECOVERY CASES

OUR PERISTALSIS HEART ASSIST PUMP DESIGNS ADDRESS ALL OF THESE REQUIREMENTS

ALLOWING MEDICAL PROFESSIONALS GREATER CONFIDENCE TREATING EXTREMELY COMPLEX CONDITIONS

MANAGEMENT

MANAGEMENT TEAM

Chief Executive Officer

Babek Khamenian

Chief Operating Officer

Michael Saveliev

Chief Technology Officer/Founder

Steve Smith

Chief Financial Officer

Jerry Browning

Chief Medical Officer

Dr. Richard Schatz

ADVISORS

MEDICAL ADVISORY BOARD

Dr. Sam Baradarian Cardiovascular Surgeon

Fellow, Adult Cardiovascular, Transplant and Mechanical Assist Device

Sharp Memorial Hospital

Dr. Richard Schatz MD, FACC, FNAI

Research  Director Cardiovascular Interventions

Director Of Gene Cell Therapy, Scripps Clinic

Adjunct Professor Of Medicine And Cardiology Duke University

DEVELOPMENT ADVISORY BOARD

Michael J. Girard P.E.

Business And Technical Leader With 33 Years In The Medical Device Industry

Focused On Cardiac Care Devices With 50 Patents In The Medical Industry

University Of St. Thomas, Minneapolis,MN, M.B.A.

University Of Illinois, Urbana, IL, B.S. Civil (Structural) Engineering

Payman Saffari

Engineering Expert Specializing In The Design And Development

Of Class II & III Medical Device Implants Including Aortic, Mitral and Tricuspid Heart Valves

M.S., Mechanical Engineering, Temple University

B.S., Aerospace Engineering, Sharif University Of Technology

Contact

For More Detailed Information Please Contact

Phap Medical

3020 Red Hill Ave, Costa Mesa, CA. 92626
Tel: 714-805-8455
Email: BKamenian@PhapMedicalllc.com

NOT AVAILABLE FOR SALE

Phap Medical heart assist pumps are currently in the product development stage and have not undergone any clinical testing. These devices are still under development, and no clinical claims regarding their safety, efficacy, or ability to support cardiovascular hemodynamics can be made at this time. The pumps are not cleared or approved for use in any capacity and remain investigational as part of ongoing product development.

DISCLAIMER

DISCLAIMER

The information provided on this website, including details about the heart assist pump industry, its market segments, competitor analysis, and technological developments, is based on assumptions, projections, and publicly available data. Due to the limited availability of specific information, these estimates are subject to change and may not fully reflect the current state of the industry. Additionally, early indications of device performance, safety, or efficacy during product development may not necessarily lead to positive clinical outcomes or regulatory approvals.

Phap Medical is currently in the product development stage, and no clinical testing has been conducted for our heart assist pumps. As such, no clinical claims regarding the safety, effectiveness, or intended use of these devices can be made at this time. All product descriptions, potential benefits, and intended applications discussed are strictly forward-looking and should not be interpreted as guarantees of future results.

We make no representations or warranties, express or implied, about the accuracy, completeness, timeliness, reliability, or suitability of the information provided. The material on this website is for informational purposes only and should not be construed as professional advice, medical guidance, or as an offer or solicitation to purchase, sell, or use any product or service mentioned. Any reliance you place on such information is strictly at your own risk.

Phap Medical reserves the right to modify, update, or remove any information on this website at any time without prior notice.

bottom of page